GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » ROE %

Heska (HSKA) ROE % : -9.64% (As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Heska ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Heska's annualized net income for the quarter that ended in Mar. 2023 was $-40.5 Mil. Heska's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $419.9 Mil. Therefore, Heska's annualized ROE % for the quarter that ended in Mar. 2023 was -9.64%.

The historical rank and industry rank for Heska's ROE % or its related term are showing as below:

HSKA' s ROE % Range Over the Past 10 Years
Min: -6.52   Med: 2.35   Max: 13.96
Current: -4.78

During the past 13 years, Heska's highest ROE % was 13.96%. The lowest was -6.52%. And the median was 2.35%.

HSKA's ROE % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.29 vs HSKA: -4.78

Heska ROE % Historical Data

The historical data trend for Heska's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heska ROE % Chart

Heska Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.25 -1.06 -6.52 -0.32 -4.64

Heska Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.24 -4.96 -0.42 -4.07 -9.64

Competitive Comparison of Heska's ROE %

For the Medical Devices subindustry, Heska's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heska's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heska's ROE % distribution charts can be found below:

* The bar in red indicates where Heska's ROE % falls into.



Heska ROE % Calculation

Heska's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-19.889/( (435.854+422.208)/ 2 )
=-19.889/429.031
=-4.64 %

Heska's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=-40.5/( (422.208+417.671)/ 2 )
=-40.5/419.9395
=-9.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.


Heska  (NAS:HSKA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-40.5/419.9395
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-40.5 / 249.524)*(249.524 / 589.2655)*(589.2655 / 419.9395)
=Net Margin %*Asset Turnover*Equity Multiplier
=-16.23 %*0.4234*1.4032
=ROA %*Equity Multiplier
=-6.87 %*1.4032
=-9.64 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-40.5/419.9395
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-40.5 / -40.604) * (-40.604 / -41.692) * (-41.692 / 249.524) * (249.524 / 589.2655) * (589.2655 / 419.9395)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9974 * 0.9739 * -16.71 % * 0.4234 * 1.4032
=-9.64 %

Note: The net income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Heska ROE % Related Terms

Thank you for viewing the detailed overview of Heska's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Heska (HSKA) Business Description

Traded in Other Exchanges
N/A
Address
3760 Rocky Mountain Avenue, Loveland, CO, USA, 80538
Heska Corp is engaged in developing, manufacturing, marketing, selling, and supporting veterinary products. The company's products include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products; and practice information management software and related software. It operates through two segments North America and International. The Company's core strategic focus on Point of Care laboratory and imaging products is included in both segments.
Executives
Joachim A. Hasenmaier director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Robert L Antin director
Mark F Furlong director 770 M WATER ST, MILWAUKEE WI 53202
Stephen L Davis director 2901 BUTTERFIELD ROAD, OAK BROOK IL 60523
Providenti Anthony C. Jr. officer: EVP, Corporate Development 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Kevin S. Wilson officer: President and COO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Eleanor F. Baker officer: EVP, Managing Dir. & COO, scil 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Christopher D. Sveen officer: CAO & General Counsel 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Nancy Wisnewski officer: EVP, Prod. Dev. & Cust. Supp 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Sharon L. Riley director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Catherine Grassman officer: EVP, CFO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason D Aroesty officer: EVP, International Diagnostics 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Bonnie J. Trowbridge director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Scott Humphrey director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason A Napolitano officer: Exec. VP, CFO & Secretary 1613 PROSPECT PARKWAY, FORT COLLINS CO 80525